AltaCorp Capital Inc Analyst on Potential of Biosynthetic Cannabinoids

AltaCorp Capital Inc Research Analyst David M. Kideckel, PhD, MBA provides an update on AltaCorp’s operations and shares his thoughts on the emerging biosynthetic cannabinoids space. Backed by Western Canada’s largest bank, ATB Financial, AltaCorp is the only firm to cover medical, pharmaceutical, and recreational cannabis from an equity research standpoint. Significantly, AltaCorp is the only company covering GW Pharmaceuticals, plc (NASDAQ:GWPH) (FRA:GWZA), makers of the drug Epidiolex. Kideckel notes that large scale equity deals are still the missing link for the sector. Kideckel discusses the emergence of biosynthetic and chemically derived cannabinoids in the space, which are cheaper to…
No products available.
Read More
The owner of this website is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon properties including, but not limited to,,,,, or
Home Privacy Policy Terms Of Use Medical Disclaimer Anti Spam Policy Contact Us Affiliate Disclosure Amazon Affiliate Disclaimer DMCA Earnings Disclaimer